HK1161884A1 - Remedies for pemphigus containing anti fas ligand antibodies fas - Google Patents

Remedies for pemphigus containing anti fas ligand antibodies fas

Info

Publication number
HK1161884A1
HK1161884A1 HK12102368.6A HK12102368A HK1161884A1 HK 1161884 A1 HK1161884 A1 HK 1161884A1 HK 12102368 A HK12102368 A HK 12102368A HK 1161884 A1 HK1161884 A1 HK 1161884A1
Authority
HK
Hong Kong
Prior art keywords
fas
remedies
containing anti
ligand antibodies
pemphigus
Prior art date
Application number
HK12102368.6A
Other languages
English (en)
Chinese (zh)
Inventor
Carlo Pincelli
Alessandra Marconi
Original Assignee
Pincell Srl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2008/010597 external-priority patent/WO2009074339A1/fr
Application filed by Pincell Srl filed Critical Pincell Srl
Publication of HK1161884A1 publication Critical patent/HK1161884A1/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2875—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF/TNF superfamily, e.g. CD70, CD95L, CD153, CD154
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/74—Inducing cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HK12102368.6A 2008-12-12 2012-03-08 Remedies for pemphigus containing anti fas ligand antibodies fas HK1161884A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
PCT/EP2008/010597 WO2009074339A1 (fr) 2007-12-12 2008-12-12 Remèdes contre le pemphigus contenant des anticorps anti-ligands fas
PCT/EP2009/067129 WO2010066914A2 (fr) 2008-12-12 2009-12-14 Remèdes contre le pemphigus, à base d'anticorps dirigés contre le ligand fas

Publications (1)

Publication Number Publication Date
HK1161884A1 true HK1161884A1 (en) 2012-08-10

Family

ID=42060995

Family Applications (1)

Application Number Title Priority Date Filing Date
HK12102368.6A HK1161884A1 (en) 2008-12-12 2012-03-08 Remedies for pemphigus containing anti fas ligand antibodies fas

Country Status (20)

Country Link
US (1) US9255150B2 (fr)
EP (1) EP2376536B1 (fr)
JP (1) JP5773882B2 (fr)
KR (1) KR101769858B1 (fr)
CN (1) CN102405234A (fr)
AU (1) AU2009326978B2 (fr)
BR (1) BRPI0922201A2 (fr)
CA (1) CA2746334C (fr)
DK (1) DK2376536T3 (fr)
ES (1) ES2534799T3 (fr)
HK (1) HK1161884A1 (fr)
IL (1) IL213213A (fr)
MX (1) MX2011006203A (fr)
NZ (1) NZ593312A (fr)
PL (1) PL2376536T3 (fr)
PT (1) PT2376536E (fr)
RU (1) RU2556818C2 (fr)
SI (1) SI2376536T1 (fr)
WO (1) WO2010066914A2 (fr)
ZA (1) ZA201104130B (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2015165973A1 (fr) * 2014-04-29 2015-11-05 Apogenix Gmbh Anticorps anti-cd95l de diagnostic
EP3353208B1 (fr) 2015-09-23 2024-08-07 Apogenix AG Anticorps anti-cd95l
RU2613718C1 (ru) * 2015-11-24 2017-03-21 Федеральное государственное бюджетное учреждение "Государственный научный центр дерматовенерологии и косметологии" Минздрава России (ФГБУ ГНЦДК Минздрава России) Способ моделирования пузырчатки у мышей методом введения иммуноглобулинов класса g
WO2023138521A1 (fr) * 2022-01-21 2023-07-27 北京三诺佳邑生物技术有限责任公司 Anticorps reconnaissant spécifiquement fasl et application associée
WO2024200287A1 (fr) * 2023-03-24 2024-10-03 Pincell S.R.L. Anticorps anti-ligand fas (fasl) utilisés dans le traitement de maladies sjs/ten

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE69636170T2 (de) 1995-03-20 2006-11-02 Okumura, Ko Monoklonaler antikörper, der spezifisch mit dem fas-liganden reagiert, und verfahren zu seiner herstellung
US6114507A (en) * 1995-06-30 2000-09-05 Mochida Pharmaceutical Co., Ltd. Anti-Fas ligand antibody and assay method using the anti-Fas ligand antibody
EP0842948B1 (fr) 1995-06-30 2009-04-22 Mochida Pharmaceutical Co., Ltd. ANTICORPS ANTI Fas LIGAND ET PROCEDE D'UTILISATION
CA2264968A1 (fr) 1996-09-02 1998-03-12 Sumitomo Electric Industries, Ltd. Immunoglobuline humanisee reagissant specifiquement avec un ligand fas ou l'un de ses fragments actifs et region d'induction d'apoptose prenant naissance dans un ligand fas
US7262277B2 (en) 2002-03-21 2007-08-28 Eli Lilly And Company Antagonistic anti-hFAS ligand human antibodies and fragments thereof
NZ602964A (en) * 2007-12-12 2013-06-28 Pincell Srl Remedies for pemphigus containing anti fas ligand antibodies
FR2933264B1 (fr) 2008-06-25 2012-10-26 Actimagine Procede d'authentification d'un utilisateur d'un service sur terminal mobile.

Also Published As

Publication number Publication date
NZ593312A (en) 2013-02-22
US9255150B2 (en) 2016-02-09
DK2376536T3 (en) 2015-06-08
IL213213A (en) 2015-10-29
MX2011006203A (es) 2011-07-20
AU2009326978A1 (en) 2011-07-07
EP2376536A2 (fr) 2011-10-19
CA2746334A1 (fr) 2010-06-17
RU2011128702A (ru) 2013-01-20
SI2376536T1 (sl) 2015-04-30
KR101769858B1 (ko) 2017-08-21
KR20110094327A (ko) 2011-08-23
JP5773882B2 (ja) 2015-09-02
WO2010066914A2 (fr) 2010-06-17
ZA201104130B (en) 2012-02-29
JP2012511550A (ja) 2012-05-24
CN102405234A (zh) 2012-04-04
CA2746334C (fr) 2018-06-12
AU2009326978B2 (en) 2013-09-12
PT2376536E (pt) 2015-05-11
IL213213A0 (en) 2011-07-31
BRPI0922201A2 (pt) 2015-12-29
RU2556818C2 (ru) 2015-07-20
PL2376536T3 (pl) 2015-10-30
US20110243946A1 (en) 2011-10-06
ES2534799T3 (es) 2015-04-29
EP2376536B1 (fr) 2015-02-25
WO2010066914A3 (fr) 2010-09-02

Similar Documents

Publication Publication Date Title
HRP20150224T1 (en) Anti mif antibodies
IL226112A0 (en) Antibodies against met–c
EP2609536A4 (fr) Registre de chaîne séquentielle pour une connaissance d'événements
PT3023438T (pt) Anticorpos anti-gitr
IL206280A0 (en) Remedies for pemphigus containing anti fas ligand antibodies
HK1173668A1 (zh) 胰島素受體結合的抗體
ZA201106983B (en) Soluble "heavy-chain only" antibodies
IL225965A0 (en) Antibodies that bind soluble ligands to the t cell receptor
EP2314628A4 (fr) Anticorps anti-cd27
EP2374883A4 (fr) Anticorps anti-cd4
SI2636736T1 (sl) Novo anti-dr5 protitelesce
EP2331134A4 (fr) Anticorps anti-cancer pancréatique
IL217066A0 (en) Anti notch-1 antibodies
PL2617734T3 (pl) Ludzkie przeciwciała przeciwko TSHR
EG26315A (en) Particulate filter
HK1161884A1 (en) Remedies for pemphigus containing anti fas ligand antibodies fas
GB0909435D0 (en) Nanoparticle for biomolecule delivery
TWI350758B (en) Pharmaceutical composition for activating fas/fas ligand pathway